# Longduoduo Co Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Longduoduo Co Ltd). ## Overview Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct healthcare services and commissions earned as a sales agent for Inner Mongolia Honghai Health Management Co., Ltd. The business has shifted heavily toward agency commissions, making it more of a healthcare distribution and referral platform than a pure service clinic operator. ## Products & services • Healthcare services: Immunological Ozonated Autohemotherapy • Meridian-regulating and Consciousness-restoring Iatrotechnics • Assay and PRP services • Sales-agent commissions for Honghai preventive healthcare solutions • Healthcare service referrals through operating subsidiaries - **Direct healthcare services** (3%) — In-clinic or direct patient services such as autohemotherapy, assay, and PRP offerings. - **Sales agency commissions** (97%) — Commission income earned from selling Honghai-administered preventive healthcare solutions. - Healthcare services including Immunological Ozonated Autohemotherapy - Meridian-regulating and Consciousness-restoring Iatrotechnics - Assay and PRP-related healthcare services - Sales-agent commissions for Honghai preventive healthcare solutions - Referral and distribution support through local operating entities ## Customers The company serves consumers in Inner Mongolia and nearby markets who purchase preventive or alternative healthcare services, often through local operating entities. A much larger share of revenue now comes from customers referred into Honghai's healthcare solutions, with Longduoduo acting as the sales agent and earning commissions. Demand appears sensitive to local economic conditions and discretionary health spending. - **Direct healthcare patients** (secondary) — Individuals purchasing in-house healthcare services such as autohemotherapy, PRP, assay and related treatments. - **Honghai-referred customers** (primary) — Consumers who buy preventive healthcare solutions administered by Honghai, generating commissions for Longduoduo. - **Local discretionary health spenders** (secondary) — Households in Inner Mongolia and Beijing that spend on non-essential healthcare services when economic conditions allow. - Local consumers buying preventive or alternative healthcare services - Patients seeking autohemotherapy, PRP, assay and related services - Customers referred into Honghai healthcare solutions - Price-sensitive households reducing discretionary health spending - Clients in Inner Mongolia's major cities and Beijing ## Geography Operations are concentrated in Inner Mongolia, China, with entities in Huhhot, Ulanqab, Baotou and Ordos, plus one entity in Beijing. The company also references U.S. capital markets as a funding source, but its operating revenue is generated in China, making it exposed to Chinese consumer demand and PRC regulatory conditions. - **Inner Mongolia, China** (100%) — Operating and revenue-generating business is concentrated in Inner Mongolia cities. - Operating entities are based in Inner Mongolia cities and Beijing - Core business activity is concentrated in Huhhot, Ulanqab, Baotou and Ordos - Revenue is generated in China, not the United States - U.S. capital markets are important for future financing plans - PRC listing and cybersecurity rules can affect access to external capital ## Strategy Management is focused on funding growth, improving operating policies, and balancing customer prepayments with working capital needs. The company also seeks access to U.S. public markets for financing, while continuing to rely on Honghai commissions as the main revenue engine. Its near-term strategy is defensive as well as expansionary: preserve liquidity, stabilize demand, and reduce dependence on a single relationship. - **Secure external financing access** (short-term) — Growth depends on capital for expansion, but PRC listing approvals may delay or block fundraising. - **Stabilize operating cash flow** (short-term) — The company has limited scale and needs cash generation to fund obligations and expansion. - **Reduce dependence on one counterparty** (medium-term) — Honghai commissions represent the vast majority of revenue, creating concentration risk. - Raise capital through U.S. securities markets if listing access is secured - Improve operating policies to support profitability and liquidity - Balance customer deposits, prepayments and deferred revenue - Use Honghai agency business to drive current revenue - Maintain support from majority shareholder if needed ## Risks The biggest risk is customer and revenue concentration: most revenue comes from Honghai commissions, so any disruption to that relationship would materially hurt results. The company is also exposed to PRC regulatory approval risk for overseas listings and to weak consumer spending in China, which can reduce demand for discretionary healthcare services. As a small operator with limited scale, it also faces liquidity pressure, going-concern risk, and execution risk in trying to expand while revenue remains volatile. - **Dependence on Honghai commissions** [critical] — Over 97% of annual revenue came from one sales agency relationship, so termination or repricing would sharply reduce income. - **PRC overseas listing approval risk** [high] — Future financing through U.S. markets may require CSRC approval, which could be delayed or denied. - **Weak discretionary health spending** [high] — Management cited a softer economic environment and lower customer health expenditures. - **Going-concern and liquidity pressure** [high] — The company expects to rely on operations, public offering proceeds or debt financing to fund growth and obligations. - **China regulatory and cybersecurity uncertainty** [medium] — PRC rules on overseas listings and data review could affect quotation and compliance costs. - Revenue concentration in Honghai creates major counterparty dependence - PRC overseas listing approvals could restrict access to capital - Weak consumer spending reduces demand for discretionary healthcare services - Going-concern risk if operations and financing do not improve - China regulatory and cybersecurity rules may affect U.S. quotation ## Accounting Revenue recognition is central because the company earns both service revenue and commission revenue, and the mix has shifted heavily toward agency commissions. Deferred revenue and customer prepayments are also important because the company carries material advance payments from customers, which affects timing of reported revenue and working capital. Management also highlights estimates for bad debts, impairment, contingencies and litigation, all of which can move earnings in a small business with volatile demand. - **Revenue recognition for commissions and healthcare services** — Revenue mix and gross profit - **Deferred revenue and customer prepayments** — Working capital and revenue timing - **Allowance for doubtful accounts** — Receivables and earnings - **Impairment and contingency estimates** — Potential earnings volatility - Commission revenue vs direct service revenue affects mix and margins - Deferred revenue and prepayments affect timing of recognized sales - Bad debt estimates matter if customer collections weaken - Impairment and contingency estimates can affect small-company earnings - Quarterly revenue swings make period comparisons less reliable --- *Last updated: 2026-04-28T20:23:25.022002+00:00*